Seres Therapeutics Announces Appointment of Thomas J. DesRosier as Chief Legal Officer and Executive Vice
President
Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has appointed
Thomas J. DesRosier as Chief Legal Officer and Executive Vice President. DesRosier will be responsible for global legal operations,
as well as corporate compliance and quality assurance. He will also act as Secretary for Seres’ Leadership Team and its Board of
Directors.
“Tom is a highly seasoned, proven biopharma leader who will strengthen our leadership team at a crucial stage in our growth and
development,” said Roger Pomerantz, M.D., President, Chief Executive Officer, and Chairman of Seres. “Tom’s broad experience
representing and advising biopharmaceutical companies, both large and small, will be invaluable as we advance our pipeline and work
to commercialize our first-in-field microbiome therapeutics worldwide. In addition, Tom’s expertise as an intellectual property
attorney will be of great value as we continue to further expand Seres’ robust microbiome patent portfolio.”
DesRosier brings more than 30 years of experience in the biopharmaceutical industry. Most recently, he served as Chief Legal and
Administrative Officer at ARIAD Pharmaceuticals, and before that he held the same position at Cubist Pharmaceuticals, where he led
the Cubist team during the company’s acquisition by Merck. Previously, he served as Senior Vice President and General Counsel,
North America of Sanofi, a position he assumed in 2011 after Sanofi acquired Genzyme Corporation, where he was Senior Vice
President and Chief Legal Officer. Prior to his 12-year tenure at Genzyme, DesRosier held senior legal positions at Wyeth
Pharmaceuticals, Genetic Institute, and E.I. DuPont de Nemours. He received his J.D. from Wake Forest University School of Law and
his Bachelor of Arts in chemistry from the University of Vermont.
“I am thrilled to join Seres as it extends its leadership position in the emerging microbiome therapeutics area,” said
DesRosier. “Seres is performing truly innovative research to develop important new therapies for patients with serious diseases, in
a whole new area of biomedicine. I look forward to working with their excellent and professional leadership team to bring the
first-ever microbiome therapeutics forward to patients.”
About Seres Therapeutics
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that
are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity
and function is imbalanced. Seres’ most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a
clinical benefit in patients with recurring Clostridium difficile infection (CDI) and is currently being evaluated in a
Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres’
second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis
(UC). For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements regarding the future benefits anticipated from Tom DesRosier’s
employment, the impact that Seres can have on diseases and the ability to commercialize therapies.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the following: we have incurred significant losses, are not
currently profitable and may never become profitable; our need for additional funding, which may not be available; our limited
operating history; the unpredictable nature of our early stage development efforts for marketable drugs; the unproven approach to
therapeutic intervention of our microbiome therapeutics; the lengthy and expensive process of clinical drug development, which has
an uncertain outcome; potential delays in enrollment of patients which could affect the receipt of necessary regulatory approvals;
potential delays in regulatory approval, which would impact the ability to commercialize our product candidates and affect our
ability to generate revenue; any fast track or Breakthrough Therapy designation may not lead to faster development, regulatory
approval or marketing approval; our possible inability to receive orphan drug designation should we choose to seek it; our reliance
on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; our
reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and
commercialization efforts; our lack of experience in manufacturing our product candidates; the potential failure of our product
candidates to be accepted on the market by the medical community; our lack of experience selling, marketing and distributing
products and our lack of internal capability to do so; failure to compete successfully against other drug companies; potential
competition from biosimilars; failure to obtain marketing approval internationally; post-marketing restrictions or withdrawal from
the market; anti-kickback, fraud, abuse, and other healthcare laws and regulations exposing us to potential criminal sanctions;
recently enacted or future legislation; compliance with environmental, health, and safety laws and regulations; protection of our
proprietary technology; protection of the confidentiality of our trade secrets; changes in United States patent law; potential
lawsuits for infringement of third-party intellectual property; our patents being found invalid or unenforceable; compliance with
patent regulations; claims challenging the inventorship or ownership of our patents and other intellectual property; claims
asserting that we or our employees misappropriated a third-party’s intellectual property or otherwise claiming ownership of what we
regard as our intellectual property; adequate protection of our trademarks; ability to attract and retain key executives; managing
our growth could result in difficulties; risks associated with international operations; potential system failures; the price of
our common stock may fluctuate substantially; our executive officers, directors, and principal stockholders have the ability to
control all matters submitted to the stockholders; a significant portion of our total outstanding shares are eligible to be sold
into the market in the near future; unfavorable or lacking analyst research or reports; and we may be subject to securities class
action litigation. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K
filed with the Securities and Exchange Commission, or SEC, on March 14, 2016 and our other reports filed with the SEC could cause
actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our
views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to
the date of this press release.
Seres Therapeutics
IR and PR Contact:
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160516005206/en/